0000950142-22-001324.txt : 20220406
0000950142-22-001324.hdr.sgml : 20220406
20220406175421
ACCESSION NUMBER: 0000950142-22-001324
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220404
FILED AS OF DATE: 20220406
DATE AS OF CHANGE: 20220406
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Casdin Eli
CENTRAL INDEX KEY: 0001534264
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34180
FILM NUMBER: 22811588
MAIL ADDRESS:
STREET 1: 1350 AVENUE OF THE AMERICAS
STREET 2: SUITE 1140
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC.
CENTRAL INDEX KEY: 0001162194
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 770513190
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 TOWER PLACE
STREET 2: SUITE 2000
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6502666000
MAIL ADDRESS:
STREET 1: 2 TOWER PLACE
STREET 2: SUITE 2000
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: FLUIDIGM CORP
DATE OF NAME CHANGE: 20011113
4
1
es220241790_4-eclab.xml
OWNERSHIP DOCUMENT
X0306
4
2022-04-04
0
0001162194
STANDARD BIOTOOLS INC.
LAB
0001534264
Casdin Eli
C/O STANDARD BIOTOOLS INC.
2 TOWER PLACE, SUITE 2000
SAN FRANCISCO
CA
94080
1
0
1
0
Common Stock
2022-04-04
4
A
0
15852
0
A
15852
D
Series B-1 Convertible Preferred Stock
2022-04-04
4
A
0
127780
A
Common Stock
37582346
127780
I
See footnote
Stock Option (Right to Buy)
3.99
2022-04-04
4
A
0
23401
0
A
2032-04-04
Common Stock
23401
23401
D
Represents Restricted Stock Units that vest in four equal annual increments beginning April 4, 2023.
Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock.
On April 4, 2022, the Issuer issued the Series B-1 Preferred Stock (i) in exchange for aggregate cash consideration of $112.5 million, pursuant to the Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, among the Issuer, Casdin Partners Master Fund, L.P. ("Casdin Master Fund") and Casdin Private Growth Equity Fund II, L.P. ("Casdin Private Growth Fund") and (ii) upon the conversion of $12.5 million aggregate principal amount of term loans, including accrued and unpaid interest, pursuant to the Series B-1 Loan Agreement, dated as of January 23, 2022, among the Issuer, Casdin Master Fund and Casdin Private Growth Fund.
These shares are held by Casdin Master Fund and Casdin Private Growth Fund. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Master Fund and Casdin Private Growth Fund. Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Master Fund and Casdin Private Growth Equity Fund II GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Fund. Eli Casdin is the managing member of Casdin Capital, Casdin Partners GP and Casdin Private Growth GP. Each of Casdin Capital, Casdin Partners GP, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any.
The Option becomes exercisable in four equal annual increments beginning on April 4, 2023.
/s/ Eli Casdin
2022-04-06